市場調查報告書
商品編碼
1053812

Truning Drag Delivery System全球市場增長機會和工業預測(PDDS)(2021-2030):產品和應用(哮喘,慢性阻塞性肺病,囊性纖維化),分佈途徑

Pulmonary Drug Delivery Systems Market by Product, Application (Asthma, Chronic Obstructive Pulmonary Diseases, and Cystic Fibrosis), and Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021--2030

出版日期: | 出版商: Allied Market Research | 英文 255 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球肺藥遞送系統(PDD)的市場規模從2020年的2020美元到2020美元到2030美元的49,782.76億美元留下了6.08%,而2030年的¥91,128.61百萬日元,預計將增加美國的規模美元。

Glung的肺藥輸送系統(PDDS)市場增長是通過污染和技術進步的增加推動。此外,吸煙培養的增加導致COPD患者數量增加。空氣污染也被認為在預測期間促進市場增長,因為它會導致支氣管和肺的炎症。 PDD具有有效的優點,強調重要性,因為它可以通過急性肺部痙攣和COPD來改善症狀。另一方面,PDD可能具有高價格,因此市場增長可能有限。

在本報告中,我們調查了全球肺部藥物交付系統(PDD)的市場,分析市場定義和概述,市場影響因素,市場規模過渡,預測,產品,使用,分銷路線,區域·我們總結了崩潰,競爭環境,主要公司的簡介,例如主要國家/地區等各種病區。

內容

第1章簡介

第2章執行摘要

第3章市場激情

  • 市場定義和範圍
  • 主要調查結果
  • Porter的五個力分析
  • 主要公司的定位
  • 市場力學
    • 促銷因素
    • 抑制因子
    • 市場機會
    • 影響分析
    covid-19:影響分析

第4章氣球拖動交付系統(PDDS)市場:基於產品的

  • 概述
  • 主要市場趨勢,增長因素,機遇
  • 市場規模/預測:按地區
  • 市場分析:農村
  • 市場規模,預測:按類型
  • 乾粉吸入器
    • 單劑量吸入器
    • 多索吸入器
  • 定量吸入器
    • 手動壓力吸入器
    • 呼吸操作壓力吸入器
  • 霧化器
    • Jetnebolizer
    • 超聲波雜草機
    • 振動網霧化器

第5章氣球藥物輸送系統(PDDS)市場:應用

  • 概述
  • 哮喘
  • 慢性阻塞性肺病(COPD)
  • 囊性纖維化
    • 主要市場趨勢,增長因素,機遇
    • 市場規模/預測:按地區
    • 市場分析:農村

第6章氣球藥物送貨系統(PDDS)市場:分銷路徑的分銷路徑

  • 概述
  • 零售藥房
  • 醫院藥房
  • 電子商務
    • 主要市場趨勢,增長因素,機遇
    • 市場規模/預測:按地區
    • 市場分析:農村

第7章氣球拖動交付系統(PDDS)市場:區域

  • 概述
  • 北美
  • 歐洲
  • 亞太地區
  • 拉丁美洲·中東·非洲
    • 主要市場趨勢,增長因素,機遇
    • PDDS市場:產品按產品
    • PDDS市場:通過申請
    • PDDS市場:通過分銷路徑
    • 市場規模,預測:按國家/地區

第8章公司配置文件

  • M company
  • aerogen
  • Astrazeneca PLC
  • Boehringer Ingelheim GmbH
  • Briggs Healthcare
  • Clement Clarke International
  • glaxosmithkline plc
  • janssen
  • Koninklijke Philips N.v.(飛利浦)
  • Novartis AG
目錄
Product Code: LI_182944 / A02607

The global pulmonary drug delivery systems market was valued at $49782.76 million in 2020, and is estimated to reach $ 91,128.61 million by 2030, growing at a CAGR of 6.08% from 2021 to 2030.

Targeted drug delivery system (TDDS) is a system of directing the drug directly into its targeted body site. Pulmonary drug delivery system (PDDS) is a type of targeted drug delivery system in which medicine is administered by inhalation method. PDDS has an advantage of quick onset of action over any other route of administration and plays an important role in asthma and chronic obstructive pulmonary disease (COPD). PDDS is a special type of device that is known as Aerosol. It is a pressurized dosage form containing one or more drugs which upon actuation emit a fine dispersed liquid and/or solid materials in gaseous medium. By device, PDDS is divided into nebulizer, metered dose inhaler, and dry powder inhaler.

The growth of the global pulmonary drug delivery market is driven by the rise in air pollution, and technical advancements. Furthermore, the rise in smoking culture is responsible for the increase in the number of COPD patients. Furthermore, air pollution causes inflammation of the bronchi & lungs, which is likely to enhance the market growth during the forecast period. According to the World Health Organization (WHO), in 2018, 9 out of 10 people inhale air that contain high levels of pollutants and an alarming death of 7 million people by ambient (outdoor) and household air pollution was noted. Pulmonary drug delivery has the advantage of quick onset time, which provides immediate relief in acute pulmonary spasms and COPD, emphasizing the importance of PDDS. The global PDDS market is expected to grow as it can be an alternative and effective targeted drug delivery option in the case of COVID-19. However, the high price of a pulmonary drug delivery system can limit the market growth. As per reports of CDC, the total treatment cost for asthma is $7 billion and For COPD is $5 billion, 2020.

The pulmonary drug delivery market is segmented on the basis of product, application, distribution channel, and region. By product, the market is divided into dry powder inhaler, metered dose inhaler, and nebulizer. The dry powder inhaler segment is further bifurcated into single dose inhaler and multi dose inhaler. The metered dose inhaler segment is further divided into manually-actuated pressurized inhaler and breath-actuated pressurized inhaler. The nebulizers segment is further classified into jet nebulizer, ultrasonic wave nebulizer, and vibrating mesh nebulizer.

By application, it is classified into asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and others. By distribution channel, it is categorized into retail pharmacies, hospital pharmacies, and e-commerce. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

  • The major companies profiled in the report include AstraZeneca plc, Boehringer Ingelheim Gmbh, GlaxoSmithKline plc, Novartis AG, Koninklijke Philips N.V., 3M company, Actelion Pharmaceuticals Ltd(Janssen), Clement, Clarke International, Briggs Healthcare and Aerogen

KEY BENEFITS FOR STAKEHOLDERS

  • The report provides an in-depth analysis of the global pulmonary drug delivery systems market size along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
  • A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities.
  • The profiles and growth strategies of the key market players are thoroughly analyzed to understand the competitive outlook of the global pulmonary drug delivery systems market.

KEY MARKET SEGMENTS

By Product

  • Dry powder inhaler
  • Single dose inhaler
  • Multi dose inhaler
  • Metered dose inhaler
  • Manually-Actuated Pressurized Inhaler
  • Breath-Actuated Pressurized Inhaler
  • Nebulizer
  • Jet Nebulizer
  • Ultrasonic Wave Nebulizer
  • Vibrating Mesh Nebulizer

By Application

  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Cystic Fibrosis
  • Others

By Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • E-commerce

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

KEY MARKET PLAYERS

  • AstraZeneca plc
  • Boehringer Ingelheim Gmbh
  • GlaxoSmithKline plc
  • Novartis AG
  • Koninklijke Philips N.V.
  • 3M company
  • Janssen (Johnson & Johnson)
  • Clement Clarke International
  • Briggs Healthcare
  • Aerogen

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key Benefits for Stakeholders
  • 1.3.Key market segments
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
    • 3.2.2.Top winning strategies
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning, 2020
  • 3.5.Market dynamics
    • 3.5.1.Drivers
      • 3.5.1.1.Increase in prevalence of pulmonary diseases
      • 3.5.1.2.Increase in technological advancement in PDDS
      • 3.5.1.3.Increase in Government policies and awareness programs by private organization
    • 3.5.2.Restraint
      • 3.5.2.1.High cost of pulmonary drug delivery system
    • 3.5.3.Opportunity
      • 3.5.3.1.Increase in research and development in pulmonary drug delivery system.
    • 3.5.4.Impact analysis
  • 3.6.Impact analysis of COVID-19 on the pulmonary drug delivery systems market

CHAPTER 4:PULMONARY DRUG DELIVERY SYSTEM, BY PRODUCT

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Dry powder inhaler
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Dry powder inhaler, by type
      • 4.2.2.1.Market size and forecast
      • 4.2.2.2.Single Dose Inhaler
      • 4.2.2.2.1.Market size and forecast
      • 4.2.2.3.Multi Dose Inhaler
      • 4.2.2.3.1.Market size and forecast
    • 4.2.3.Market size and forecast, by region
    • 4.2.4.Market analysis, by country
  • 4.3.Metered dose inhaler
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast, by region
    • 4.3.3.Metered dose inhaler, by type
      • 4.3.3.1.Market size and forecast
      • 4.3.3.2.Manually actuated pressurized inhaler
      • 4.3.3.2.1.Market size and forecast
      • 4.3.3.3.Breath actuated pressurized inhaler
      • 4.3.3.3.1.Market size and forecast
    • 4.3.4.Market analysis, by country
  • 4.4.Nebulizer
    • 4.4.1.Key market trends, growth factors, and opportunities
    • 4.4.2.Nebulizer, by type
      • 4.4.2.1.Market size and forecast
      • 4.4.2.2.Jet nebulizer
      • 4.4.2.2.1.Market size and forecast
      • 4.4.2.3.Ultrasonic wave nebulizer
      • 4.4.2.3.1.Market size and forecast
      • 4.4.2.4.Vibrating mesh nebulizer
      • 4.4.2.4.1.Market size and forecast
    • 4.4.3.Market size and forecast, by region
    • 4.4.4.Market analysis, by country

CHAPTER 5:PULMONARY DRUG DELIVERY SYSTEM, BY APPLICATION

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Asthma
    • 5.2.1.Key market trends, growth factors, and opportunities
    • 5.2.2.Market size and forecast, by region
    • 5.2.3.Market analysis, by country
  • 5.3.Chronic obstructive pulmonary disease (COPD)
    • 5.3.1.Key market trends, growth factors, and opportunities
    • 5.3.2.Market size and forecast, by region
    • 5.3.3.Market analysis, by country
  • 5.4.Cystic fibrosis
    • 5.4.1.Key market trends, growth factors, and opportunities
    • 5.4.2.Market size and forecast, by region
    • 5.4.3.Market analysis, by country

CHAPTER 6:PULMONARY DRUG DELIVERY SYSTEM, BY DISTRIBUTION CHANNEL

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Retail pharmacies
    • 6.2.1.Key market trends, growth factors, and opportunities
    • 6.2.2.Market size and forecast, by region
    • 6.2.3.Market analysis, by country
  • 6.3.Hospital pharmacies
    • 6.3.1.Key market trends, growth factors, and opportunities
    • 6.3.2.Market size and forecast, by region
    • 6.3.3.Market analysis, by country
  • 6.4.E-commerce
    • 6.4.1.Key market trends, growth factors, and opportunities
    • 6.4.2.Market size and forecast, by region
    • 6.4.3.Market analysis, by country

CHAPTER 7:PULMONARY DRUG DELIVERY SYSTEM MARKET, BY REGION

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.North America
    • 7.2.1.Key market trends, growth factors, and opportunities
    • 7.2.2.North America pulmonary drug delivery system market, by product
    • 7.2.3.North America pulmonary drug delivery system market, by application
    • 7.2.4.North America pulmonary drug delivery system market, by distribution channel
    • 7.2.5.Market size and forecast, by country
      • 7.2.5.1.U.S.
      • 7.2.5.1.1.U.S. pulmonary drug delivery system market, by product
      • 7.2.5.1.2.U.S. pulmonary drug delivery system market, by application
      • 7.2.5.1.3.U.S. pulmonary drug delivery system market, by distribution channel
      • 7.2.5.2.Canada
      • 7.2.5.2.1.Canada pulmonary drug delivery system market, by product
      • 7.2.5.2.2.Canada pulmonary drug delivery system market, by application
      • 7.2.5.2.3.Canada pulmonary drug delivery system market, by distribution channel
      • 7.2.5.3.Mexico
      • 7.2.5.3.1.Mexico pulmonary drug delivery system market, by product
      • 7.2.5.3.2.Mexico pulmonary drug delivery system market, by application
      • 7.2.5.3.3.Mexico pulmonary drug delivery system market, by distribution channel
  • 7.3.Europe
    • 7.3.1.Key market trends, growth factors, and opportunities
    • 7.3.2.Europe pulmonary drug delivery system market, by product
    • 7.3.3.Europe pulmonary drug delivery systems market, by application
    • 7.3.4.Europe pulmonary drug delivery systems market, by distribution channel
    • 7.3.5.Market size and forecast, by country
      • 7.3.5.1.Germany
      • 7.3.5.1.1.Germany pulmonary drug delivery system market, by product
      • 7.3.5.1.2.Germany pulmonary drug delivery system market, by application
      • 7.3.5.1.3.Germany pulmonary drug delivery system market, by distribution channel
      • 7.3.5.2.France
      • 7.3.5.2.1.France pulmonary drug delivery system market, by product
      • 7.3.5.2.2.France pulmonary drug delivery system market, by application
      • 7.3.5.2.3.France pulmonary drug delivery system market, by distribution channel
      • 7.3.5.3.UK
      • 7.3.5.3.1.UK pulmonary drug delivery system market, by product
      • 7.3.5.3.2.UK pulmonary drug delivery system market, by application
      • 7.3.5.3.3.UK pulmonary drug delivery system market, by distribution channel
      • 7.3.5.4.Italy
      • 7.3.5.4.1.Italy pulmonary drug delivery system market, by product
      • 7.3.5.4.2.Italy pulmonary drug delivery system market, by application
      • 7.3.5.4.3.Italy pulmonary drug delivery system market, by distribution channel
      • 7.3.5.5.Spain
      • 7.3.5.5.1.Spain pulmonary drug delivery systems market, by product
      • 7.3.5.5.2.Spain pulmonary drug delivery system market, by application
      • 7.3.5.5.3.Spain pulmonary drug delivery system market, by distribution channel
      • 7.3.5.6.Rest of Europe
      • 7.3.5.6.1.Rest of Europe pulmonary drug delivery system market, by product
      • 7.3.5.6.2.Rest of Europe pulmonary drug delivery system market, by application
      • 7.3.5.6.3.Rest of Europe pulmonary drug delivery system market , by distribution channel
  • 7.4.Asia-Pacific
    • 7.4.1.Key market trends, growth factors, and opportunities
    • 7.4.2.Asia-Pacific pulmonary drug delivery system market, by product
    • 7.4.3.Asia-Pacific pulmonary drug delivery system market, by application
    • 7.4.4.Asia-Pacific pulmonary drug delivery system market, by distribution channel
    • 7.4.5.Market size and forecast, by country
      • 7.4.5.1.Japan
      • 7.4.5.1.1.Japan pulmonary drug delivery system market, by product
      • 7.4.5.1.2.Japan pulmonary drug delivery system market, by application
      • 7.4.5.1.3.Japan pulmonary drug delivery system market, by distribution channel
      • 7.4.5.2.China
      • 7.4.5.2.1.China pulmonary drug delivery system market, by product
      • 7.4.5.2.2.China pulmonary drug delivery system market, by application
      • 7.4.5.2.3.China pulmonary drug delivery system market, by distribution channel
      • 7.4.5.3.Australia
      • 7.4.5.3.1.Australia pulmonary drug delivery system market, by product
      • 7.4.5.3.2.Australia pulmonary drug delivery system market, by application
      • 7.4.5.3.3.Australia pulmonary drug delivery system market, by distribution channel
      • 7.4.5.4.India
      • 7.4.5.4.1.India pulmonary drug delivery system market, by product
      • 7.4.5.4.2.India pulmonary drug delivery system market, by application
      • 7.4.5.4.3.India pulmonary drug delivery system market, by distribution channel
      • 7.4.5.5.South Korea
      • 7.4.5.5.1.South Korea pulmonary drug delivery system market, by product
      • 7.4.5.5.2.South Korea pulmonary drug delivery system market, by application
      • 7.4.5.5.3.South Korea pulmonary drug delivery system market, by distribution channel
      • 7.4.5.6.Rest of Asia-Pacific
      • 7.4.5.6.1.Rest of Asia-Pacific pulmonary drug delivery systems market, by product
      • 7.4.5.6.2.Rest of Asia-Pacific pulmonary drug delivery system market, by application
      • 7.4.5.6.3.Rest of Asia-Pacific pulmonary drug delivery system market, by distribution channel
  • 7.5.LAMEA
    • 7.5.1.Key market trends, growth factors, and opportunities
    • 7.5.2.LAMEA pulmonary drug delivery system market, by product
    • 7.5.3.LAMEA pulmonary drug delivery system market, by application
    • 7.5.4.LAMEA pulmonary drug delivery system market, by distribution channel
    • 7.5.5.Market size and forecast, by country
      • 7.5.5.1.Brazil
      • 7.5.5.1.1.Brazil pulmonary drug delivery system market, by product
      • 7.5.5.1.2.Brazil pulmonary drug delivery system market, by application
      • 7.5.5.1.3.Brazil pulmonary drug delivery system market, by distribution channel
      • 7.5.5.2.Saudi Arabia
      • 7.5.5.2.1.Saudi Arabia pulmonary drug delivery system market, by product
      • 7.5.5.2.2.Saudi Arabia pulmonary drug delivery system market, by application
      • 7.5.5.2.3.Saudi Arabia pulmonary drug delivery system market, by distribution channel
      • 7.5.5.3.South Africa
      • 7.5.5.3.1.South Africa pulmonary drug delivery system market, by product
      • 7.5.5.3.2.South Africa pulmonary drug delivery system market, by application
      • 7.5.5.3.3.South Africa pulmonary drug delivery system market, by distribution channel
      • 7.5.5.4.Rest of LAMEA
      • 7.5.5.4.1.Rest of LAMEA pulmonary drug delivery systems market, by product
      • 7.5.5.4.2.Rest of LAMEA pulmonary drug delivery system market, by application
      • 7.5.5.4.3.Rest of LAMEA pulmonary drug delivery system market, by distribution channel

CHAPTER 8:COMPANY PROFILES

  • 8.1.3M company
    • 8.1.1.Company overview
    • 8.1.2.Company snapshot
    • 8.1.3.Operating business segments
    • 8.1.4.Product portfolio
    • 8.1.5.Business performance
  • 8.2.Aerogen
    • 8.2.1.Company overview
    • 8.2.2.Company snapshot
    • 8.2.3.Product portfolio
  • 8.3.AstraZeneca plc
    • 8.3.1.Company overview
    • 8.3.2.Company snapshot
    • 8.3.3.Operating business segments
    • 8.3.4.Product portfolio
    • 8.3.5.Business performance
  • 8.4.Boehringer Ingelheim Gmbh
    • 8.4.1.Company overview
    • 8.4.2.Company snapshot
    • 8.4.3.Operating business segments
    • 8.4.4.Product portfolio
    • 8.4.5.Business performance
  • 8.5.Briggs Healthcare
    • 8.5.1.Company overview
    • 8.5.2.Company snapshot
    • 8.5.3.Operating business segments
    • 8.5.4.Product Portfolio
  • 8.6.Clement Clarke International
    • 8.6.1.Company overview
    • 8.6.2.Company snapshot
    • 8.6.3.Operating business segments
    • 8.6.4.Product portfolio
  • 8.7.GlaxoSmithKline plc
    • 8.7.1.Company overview
    • 8.7.2.Company snapshot
    • 8.7.3.Operating business segments
    • 8.7.4.Product portfolio
    • 8.7.5.Business performance
  • 8.8.Janssen
    • 8.8.1.Company overview
    • 8.8.2.Company snapshot
    • 8.8.3.Operating business segments
    • 8.8.4.Product portfolio
    • 8.8.5.Business performance
  • 8.9.Koninklijke Philips N.V. (Philips)
    • 8.9.1.Company overview
    • 8.9.2.Company snapshot
    • 8.9.3.Operating business segments
    • 8.9.4.Product portfolio
    • 8.9.5.Business performance
  • 8.10.Novartis AG
    • 8.10.1.Company overview
    • 8.10.2.Company snapshot
    • 8.10.3.Operating business segments
    • 8.10.4.Product portfolio
    • 8.10.5.Business performance

LIST OF TABLES

  • TABLE 01.GLOBAL PULMONARY DRUG DELIVERY SYSTEM MARKET, BY THERAPY, 2020-2030 ($MILLION)
  • TABLE 02.PULMONARY DRUG DELIVERY SYSTEM MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 03.PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR DRY POWDER INHALER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 04.PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR METERED DOSE INHALER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 05.PULMONARY DRUG DELIVERY SYSTEM MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 06.PULMONARY DRUG DELIVERY SYSTEM MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 07.PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR NEBULIZER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 08.GLOBAL PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 09.PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR ASTHMA, BY REGION, 2020-2030 ($MILLION)
  • TABLE 10.PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2020-2030 ($MILLION)
  • TABLE 11.PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR CYSTIC FIBROSIS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 12.GLOBAL PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 13.PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR RETAIL PHARMACY, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 14.PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR HOSPITAL PHARMACY, BY REGION, 2020-2030 ($MILLION)
  • TABLE 15.PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR E-COMMERCE, BY REGION, 2020-2030 ($MILLION)
  • TABLE 16.PULMONARY DRUG DELIVERY SYSTEM MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 17.NORTH AMERICA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 18.NORTH AMERICA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 19.NORTH AMERICA PULMONARY DRUG DELIVERY SYSTEM MARKET , BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 20.NORTH AMERICA PULMONARY DRUG DELIVERY SYSTEM MARKET WAS VALUED, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 21.U.S. PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 22.U.S. PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 23.U.S. PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 24.CANADA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 25.CANADA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 26.CANADA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 27.MEXICO PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 28.MEXICO PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 29.MEXICO PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 30.EUROPE PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 31.EUROPE PULMONARY DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 32.EUROPE PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 33.EUROPE PULMONARY DRUG DELIVERY SYSTEMS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 34.GERMANY PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 35.GERMANY PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 36.GERMANY PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 37.FRANCE PULMONARY DRUG DELIVERY SYSTEM MARKET , BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 38.FRANCE PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 39.FRANCE PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 40.UK PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 41.UK PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 42.UK PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 43.ITALY PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 44.ITALY PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 45.ITALY PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 46.SPAIN PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 47.SPAIN PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 48.SPAIN PULMONARY DRUG DELIVERY SYSTEM MARKET BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 49.REST OF EUROPE PULMONARY DRUG DELIVERY SYSTEM MARKET , BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 50.REST OF EUROPE PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 51.REST OF EUROPE PULMONARY DRUG DELIVERY SYSTEM MARKET , BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 52.ASIA-PACIFIC PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 53.ASIA-PACIFIC PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 54.ASIA-PACIFIC PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 55.ASIA-PACIFIC PULMONARY DRUG DELIVERY SYSTEM MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 56.JAPAN PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 57.JAPAN PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 58.JAPAN PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 59.CHINA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 60.CHINA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 61.CHINA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 62.AUSTRALIA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT 2020-2030 ($MILLION)
  • TABLE 63.AUSTRALIA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 64.AUSTRALIA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 65.INDIA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 66.INDIA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 67.INDIA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 68.SOUTH KOREA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 69.SOUTH KOREA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 70.SOUTH KOREA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 71.REST OF ASIA-PACIFIC PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 72.REST OF ASIA-PACIFIC PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 73.REST OF ASIA-PACIFIC PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 74.LAMEA PULMNARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 75.LAMEA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 76.LAMEA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 77.LAMEA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 78.BRAZIL PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 79.BRAZIL PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 80.BRAZIL PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 81.SAUDI ARABIA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 82.SAUDI ARABIA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 83.SAUDI ARABIA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 84.SOUTH AFRICA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 85.SOUTH AFRICA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 86.SOUTH AFRICA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 87.REST OF LAMEA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 88.REST OF LAMEA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 89.REST OF LAMEA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 90.3M: COMPANY SNAPSHOT
  • TABLE 91.3M: OPERATING SEGMENTS
  • TABLE 92.3M: PRODUCT PORTFOLIO
  • TABLE 93.AEROGEN: COMPANY SNAPSHOT
  • TABLE 94.AEROGEN: PRODUCT PORTFOLIO
  • TABLE 95.ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 96.ASTRAZENECA SEGMENTS
  • TABLE 97.ASTRAZENECA: PRODUCT PORTFOLIO
  • TABLE 98.BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
  • TABLE 99.BOEHRINGER INGELHEIM SEGMENTS
  • TABLE 100.BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
  • TABLE 101.BRIGGS: COMPANY SNAPSHOT
  • TABLE 102.BRIGGS OPERATING SEGMENTS
  • TABLE 103.BRIGGS: PRODUCT PORTFOLIO
  • TABLE 104.CLEMENT CLARKE: COMPANY SNAPSHOT
  • TABLE 105.CLEMENT CLARKE: OPERATING SEGMENTS
  • TABLE 106.CLEMENT CLARKE: PRODUCT PORTFOLIO
  • TABLE 107.GSK: COMPANY SNAPSHOT
  • TABLE 108.GSK: OPERATING SEGMENTS
  • TABLE 109.GSK: PRODUCT PORTFOLIO
  • TABLE 110.JANSSEN: COMPANY SNAPSHOT
  • TABLE 111.JANSSEN: OPERATING SEGMENTS
  • TABLE 112.JANSSEN: PRODUCT PORTFOLIO
  • TABLE 113.PHILIPS: COMPANY SNAPSHOT
  • TABLE 114.PHILIPS: OPERATING SEGMENTS
  • TABLE 115.PHILIPS: PRODUCT PORTFOLIO
  • TABLE 116.NOVARTIS: COMPANY SNAPSHOT
  • TABLE 117.NOVARTIS: OPERATING SEGMENTS
  • TABLE 118.NOVARTIS: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.PULMONARY DRUG DELIVERY SYSTEM MARKET SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018-2021
  • FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2021
  • FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018-2021
  • FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 08.MODERATE THREAT OF SUBSTITUTES
  • FIGURE 09.MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 10.MODERATE INTENSITY OF RIVALRY
  • FIGURE 11.TOP PLAYER POSITIONING, 2020
  • FIGURE 12.IMPACT ANALYSIS
  • FIGURE 13.COMPARATIVE ANALYSIS OF PULMONARY DRUG DELIVERY SYSTMES MARKET FOR DRY POWDER INHALER, BY COUNTRY, 2020-2030 (%)
  • FIGURE 14.COMPARATIVE ANALYSIS OF PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR METERED DOSE INHALER, BY COUNTRY, 2020-2030 (%)
  • FIGURE 15.COMPARATIVE ANALYSIS OF PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR NEBULIZER, BY COUNTRY, 2020-2030 (%)
  • FIGURE 16.COMPARATIVE ANALYSIS OF PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR ASTHMA, BY COUNTRY, 2020-2030 (%)
  • FIGURE 17.COMPARATIVE ANALYSIS OF PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY COUNTRY, 2020-2030 (%)
  • FIGURE 18.COMPARATIVE ANALYSIS OF PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR CYSTIC FIBROSIS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 19.COMPARATIVE ANALYSIS OF PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2020-2030 (%)
  • FIGURE 20.COMPARATIVE ANALYSIS OF PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2020-2030 (%)
  • FIGURE 21.COMPARATIVE ANALYSIS OF PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR E-COMMERCE, BY COUNTRY, 2020-2030 (%)
  • FIGURE 22.3M: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 23.3M: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 24.3M: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 25.ASTRAZENECA: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 26.ASTRAZENECA: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 27.ASTRAZENECA: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 28.BOEHRINGER INGELHEIM: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 29.BOEHRINGER INGELHEIM: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 30.BOEHRINGER INGELHEIM: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 31.GSK: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 32.GSK: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 33.GSK REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 34.JANSSEN: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 35.JANSSEN: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 36.JANSSEN: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 37.PHILIPS: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 38.PHILIPS: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 39.PHILIPS: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 40.NOVARTIS: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 41.NOVARTIS: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 42.NOVARTIS: REVENUE SHARE BY REGION, 2020(%)